Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Quad Medicine

Request full access

Microneedle patch platform for transdermal drug delivery

Seongnam-si, South KoreaHealth

About Quad Medicine

QuadMedicine is a South Korean biotechnology company founded in 2017 by CEO Baek Seung-ki, who has over 15 years of experience in medical device research and development. The company is focused on developing drug delivery technologies centered on its Microneedle Array Patch (MAP) products, which offer a minimally invasive method for delivering drugs through the skin. This approach aims to overcome the limitations of traditional injections and oral medications, such as pain and low absorption rates.

The company's core technology involves a patch with microneedles less than 1 mm in length that efficiently deliver drugs to the dermis. QuadMedicine has developed three main platform technologies: Separable MAP (S-MAP), where the needle tip separates upon administration; Coated MAP (C-MAP), which coats active ingredients onto the microstructures; and Particle-attached MAP (P-MAP). These platforms are designed for versatility and can be applied to various formulations including vaccines, peptides, and synthetic drugs, with benefits such as precise dosing, the potential for room-temperature storage, and the convenience of self-administration.

QuadMedicine's business model incorporates a contract development and manufacturing organization (CDMO) strategy, integrating formulation development with clinical and commercial production. The company has established an aseptic automated microneedle manufacturing process to ensure quality and cost-effectiveness. QuadMedicine collaborates with global pharmaceutical companies on joint development and technology transfer projects. Notable collaborations include a partnership with LG Chem for a hepatitis B vaccine, which was the first in Korea to receive IND approval for a Phase 1 clinical trial using microneedles, and research projects with GSK plc and the RIGHT Foundation. The company's revenue streams are expected to come from milestone technology fees and future royalties from product sales.

Source: Dealroom company data

At a glance

Status
Operational
Headquarters
Seongnam-si, South Korea
Employees
5
Open positions
None listed
Dealroom signal
22.6/100
Industry
Health
Sector
Health, Drug Development, Vaccines, Immune System
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit Dec 2025 $21M — Undisclosed —
SERIES C✓Equity / VC May 2022 $17M $69M Kiwoom Investment · NH Investment & Securities —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Quad Medicine website traffic

Latest recorded traffic for Quad Medicine is 15K monthly website visits, down 11.8% over the last three months. Quad Medicine's team grew 0% over the past year.

Latest monthly visits15K 3-month web change-11.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Quad Medicine in the Seongnam-si ecosystem

Live from Dealroom

The Quad Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • SparkLabs Korea

Series B and later2 investors entered at this stage

  • Kiwoom Investment
  • NH Investment & Securities

Other known investors3 additional known investors

  • Krypton
  • Shinhan Venture Investment
  • SparkLabs Group
Employees 5 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇰🇷 South Korea100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Quad Medicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Quad Medicine’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.